Company Overview

Johnson & Johnson is a multinational healthcare company operating across the pharmaceuticals and medical technology industries. The company focuses on researching, developing, manufacturing, and marketing healthcare products used by healthcare professionals and patients worldwide. Its primary revenue is generated from prescription medicines and medical devices, serving hospitals, physicians, and healthcare systems across multiple therapeutic and procedural areas.

The company was founded in 1886 by Robert Wood Johnson, James Wood Johnson, and Edward Mead Johnson in the United States and initially specialized in ready-to-use surgical dressings. Over time, Johnson & Johnson expanded through internal research and acquisitions into a diversified healthcare enterprise. A significant structural change occurred in 2023 with the separation of its consumer health business into Kenvue, leaving Johnson & Johnson focused exclusively on pharmaceuticals and medical technology.

Business Operations

Johnson & Johnson operates through two primary business segments: Innovative Medicine and MedTech. Innovative Medicine includes prescription pharmaceutical products addressing areas such as oncology, immunology, neuroscience, infectious diseases, and cardiovascular and metabolic disorders, with a substantial portion of revenue derived from patented therapies. MedTech encompasses a broad portfolio of medical devices and technologies used in orthopedic, cardiovascular, surgical, and vision care procedures.

The company conducts operations both domestically and internationally, with research and development facilities, manufacturing sites, and commercial organizations across multiple continents. Key business units and subsidiaries include Janssen Pharmaceuticals, Ethicon, DePuy Synthes, and Abiomed, which contribute specialized technologies, devices, and therapeutic solutions. Revenue generation is driven by product sales to healthcare providers, hospitals, and distributors, supported by ongoing investment in clinical development and regulatory approvals.

Strategic Position & Investments

Johnson & Johnson’s strategic direction emphasizes innovation-led growth, portfolio optimization, and disciplined capital allocation. The company prioritizes investment in high-growth therapeutic areas such as oncology, immunology, cardiovascular disease, and advanced surgical technologies, while continuing to streamline its business following the Kenvue separation. Research and development spending remains a core component of its long-term strategy.

Major recent investments include the acquisition of Abiomed, which expanded the company’s cardiovascular device portfolio, and continued funding of late-stage pharmaceutical pipelines. Johnson & Johnson also maintains a venture capital arm that invests in emerging healthcare technologies and early-stage life sciences companies, supporting innovation in areas such as digital health, robotics, and next-generation therapeutics.

Geographic Footprint

Johnson & Johnson is headquartered in North America, with its principal executive offices in the United States. The company maintains a significant operational presence across Europe, Asia-Pacific, Latin America, and Africa, reflecting its role as a global healthcare provider.

Its products are marketed and sold in more than 60 countries, with manufacturing and research facilities strategically located to support regional demand and regulatory requirements. International markets represent a substantial portion of total revenue, and the company continues to expand its footprint in emerging markets through localized manufacturing, partnerships, and regulatory engagement.

Leadership & Governance

Johnson & Johnson is led by an experienced executive team with a governance structure designed to support long-term value creation, ethical conduct, and patient-focused innovation. The company’s leadership philosophy is guided by its longstanding corporate credo, which emphasizes responsibility to patients, employees, communities, and shareholders.

Key executives include:

• Joaquin Duato – Chairman of the Board and Chief Executive Officer
• Joseph J. Wolk – Executive Vice President and Chief Financial Officer
• Jennifer Taubert – Executive Vice President, Worldwide Chair, Innovative Medicine
• Ashley McEvoy – Executive Vice President, Worldwide Chair, MedTech
• Kathryn E. Wengel – Executive Vice President and Chief Global Supply Chain Officer

The board and executive leadership oversee corporate strategy, risk management, and capital allocation, with governance practices aligned to public company regulatory standards and long-term shareholder interests.